Filtern
Volltext vorhanden
- nein (6)
Dokumenttyp
Sprache
- Englisch (6)
Gehört zur Bibliographie
- ja (6)
Schlagworte
- 1-Methoxy-3-indolylmethyl glucosinolate (1)
- Blood protein adducts (1)
- DNA adducts (1)
- Neoglucobrassicin (1)
- Pak choi (1)
- drug design (1)
- drug metabolism (1)
- liver metabolism (1)
- molecular dynamics (1)
- molecular modeling (1)
Institut
Equol has, as have other isoflavonoids, recently gained considerable interest due to its possible health effects. However, detailed studies on the metabolism of equol are scarce. Therefore, we investigated the phase I metabolism of equol using liver microsomes from Aroclor-treated male Wistar rats as well as from a male human. The identification of the metabolites formed was elucidated using high performance liquid chromatography ( HPLC) with diode array detection, HPLC/atmospheric pressure ionization electrospray mass spectrometry, and gas chromatography-mass spectrometry, as well as reference compounds. ( +/-)-Equol was converted to 11 metabolites by the liver microsomes from Aroclorpretreated rats comprising three aromatic monohydroxylated and four aliphatic monohydroxylated as well as four dihydroxylated products. The main metabolite was identified as 3'-hydroxy-equol. Using human liver microsomes, equol was converted to six metabolites with 3'-hydroxy- and 6-hydroxy-equol as main products. Furthermore, the aliphatic hydroxylated metabolite 4-hydroxyequol, which was recently detected in human urine after soy consumption, was formed. On the basis of these findings, it is suggested that phase I metabolism of equol is part of a complex biotransformation of the soy isoflavone daidzein in humans in vivo